Description
Penn Medicine UPenn HFpEF Symposium 2023
Friday, March 24, 2023, 8:00 AM – Saturday, March 25, 2023, 7:20 PM, Smilow Center and Online, Philadelphia, PA
Penn Medicine UPenn HFpEF Symposium While the incidence of heart failure with reduced ejection fraction (HFrEF) has decreased, that of heart failure with preserved ejection fraction (HFpEF) continues to rise, accounting for ~50% of heart failure hospitalizations. Patients with HFpEF suffer mentally and physically, similar to their HFrEF counterparts, and are markedly limited in terms of their functional capacity and quality of life. Yet in contrast to HFrEF, there are few effective pharmacologic treatments for HFpEF, despite numerous clinical trials.
To address this urgent need, many clinicians and researchers have focused on this important medical and societal issue. Improved strategies now exist to diagnose this condition, and multifaceted treatment options can help to alleviate some of the morbidity of the disease. This symposium will highlight diagnostic strategies and review the evidence base for pharmacologic therapies. Treatment of comorbid conditions found in HFpEF patients will also be discussed. Additional didactics highlighting the sources of exertional intolerance in HFpEF patients will be presented, with an emphasis on cardiopulmonary exercise testing.
Penn Medicine UPenn HFpEF Symposium The topics chosen for this conference represent the state-of-the-art in HFpEF management, incorporating the expertise of numerous disciplines including cardiology, pulmonology, radiology, sleep medicine, and endocrinology. The meeting is intended to provide an in-depth summary of HFpEF management to practicing clinicians across numerous disciplines, including Physicians, Nurse Practitioners, and Physician Assistants.
After completing this activity, participants should be able to:
- Review the diagnostic criteria for HFpEF, including when to use advanced imaging or hemodynamic assessment
- Discuss HFpEF mimickers, including amyloidosis, sarcoidosis, and inherited cardiomyopathies
- Discuss the role of non-cardiac structures (such as the arterial system and other organs) in the pathogenesis and treatment of HFpEF
- Describe the electrophysiologic manifestations of HFpEF and their treatments
- Discuss novel therapies that are on the horizon for HFpEF
- Review the potential causes of exertional intolerance in HFpEF patients.
Penn Medicine UPenn HFpEF Symposium
 Topics:
- Acute nitroglycerin use worsens ventilatory efficiency during exercise in patients with heart failure with preserved ejection fraction.mp4
Addressing Disparities in the Management of HFpEF and its Comorbidities.mp4
Addressing Disparities in the Management of HFpEF and its Comorbidities.pdf
Advanced Echo Techniques to Diagnose HFpEF.mp4
Advanced Echo Techniques to Diagnose HFpEF.pdf
Advanced Imaging – PET and cMRI in HFpEF.mp4
Advanced Imaging – PET and cMRI in HFpEF.pdf
Atrial Fibrillation in HFpEF – Should We Ablate Sooner..mp4
Atrial Fibrillation in HFpEF – Should We Ablate Sooner..pdf
Case Presentation – Cardiology Fellows Junior Faculty 2.mp4
Case Presentation – Cardiology Fellows Junior Faculty 2.pdf
Case Presentation – Cardiology Fellows Junior Faculty.mp4
Case Presentation – Cardiology Fellows Junior Faculty.pdf
Case Presentation- HF Cardiology Fellow 2.mp4
Case Presentation- HF Cardiology Fellow 2.pdf
Case Presentation- HF Cardiology Fellow.mp4
Case Presentation- HF Cardiology Fellow.pdf
Chronotropic Incompetence- Modulating Sinus Rhythm and Pacing.mp4
Chronotropic Incompetence- Modulating Sinus Rhythm and Pacing.pdf
Clinical Factors and Biomarkers – Scoring Systems (e.g. H2FPEF).mp4
Clinical Factors and Biomarkers – Scoring Systems (e.g. H2FPEF).pdf
Debate- It’s the Heart! High Pressures ‘Limit’ Exercise in HFpEF.mp4
Debate- It’s the Heart! High Pressures ‘Limit’ Exercise in HFpEF.pdf
Debate- The Heart Isn’t Normal but It’s Not Everything – Peripheral Limitations in HFpEF.pdf
Development of novel mouse models recapitulating Heart Failure with preserved Ejection Fraction.mp4
Diuretics and Overcoming Resistance.mp4
Diuretics and Overcoming Resistance.pdf
Drugs to Modulate Contractility – Levosimendan and Mavacamten.mp4
Drugs to Modulate Contractility – Levosimendan and Mavacamten.pdf
EpiProteomic Profiling Of Human Heart Biopsies Reveals Histone H3k27acMediated Metabolic Dysfunction In Heart Failure With Preserved Ejection Fraction.mp4
Exercise Physiology, as seen Through a CPET Test.mp4
Exercise Physiology, as seen Through a CPET Test.pdf
Fibrosis In HFpEF – What it Means and What to do About it. The New and the Old.mp4
Fibrosis In HFpEF – What it Means and What to do About it. The New and the Old.pdf
HFpEF Epidemiology – a Growing Problem.mp4
HFpEF Epidemiology – a Growing Problem.pdf
HFpEF – A Global Perspective.mp4
HFpEF – A Global Perspective.pdf
HFpEF23_Brochure_v24.pdf
Implantable PA Monitors in HFpEF.mp4
Implantable PA Monitors in HFpEF.pdf
Intracardiac Shunt Devices.mp4
Intracardiac Shunt Devices.pdf
Keynote- HFpEF Guidelines – Phenogroups to Guide Therapies.mp4
Keynote- HFpEF Guidelines – Phenogroups to Guide Therapies.pdf
Keynote- Redefining the Pathobiology of HFpEF.mp4
Keynote- Redefining the Pathobiology of HFpEF.pdf
Keynote- The Future of HFpEF Treatment.pdf
Lung Disease and Pulmonary Hypertension in HFpEF.mp4
Lung Disease and Pulmonary Hypertension in HFpEF.pdf
Management of Obesity – Drugs and Surgical Considerations.mp4
Management of Obesity – Drugs and Surgical Considerations.pdf
Mechanisms limiting stroke volume reserve in patients with HFpEF- the potential role of interventricular dependence in the upright position.mp4
Microvascular Dysfunction in HFpEF.mp4
Microvascular Dysfunction in HFpEF.pdf
MRAs and ARNIs – Trials, Tribulations, and Recommendations.mp4
MRAs and ARNIs – Trials, Tribulations, and Recommendations.pdf
Overcoming the Sedentary Lifestyle – Exercise as Prevention and Treatment for HFpEF.mp4
Overcoming the Sedentary Lifestyle – Exercise as Prevention and Treatment for HFpEF.pdf
Paracardial fat is related to adverse ventricular interdependence in heart failure with preserved ejection fraction.mp4
Recap of Day 1 and Intro to Day 2.mp4
Recap of Day 1 and Intro to Day 2.pdf
Regulation Of Skeletal Muscle Blood Flow And Oxygen Utilization In Heart Failure With Preserved Ejection Fraction During Small Muscle Mass Exercise.mp4
SGLT2i- Outcomes and Controversies.mp4
SGLT2i- Outcomes and Controversies.pdf
Sleep Apnea in HFpEF.pdf
Splanchnic Nerve Modulation in HFpEF.mp4
Splanchnic Nerve Modulation in HFpEF.pdf
To the Cath Lab – Manuevers and Challenges to Make the Diagnosis and When to Biopsy.mp4
To the Cath Lab – Manuevers and Challenges to Make the Diagnosis and When to Biopsy.pdf
Update on Amyloid Therapies.mp4
Update on Amyloid Therapies.pdf
Vasohibin Inhibition Improves Relaxation Kinetics in a Rodent Model of HFpEF.mp4
Wholebody macronutrient tracing in a mouse model of heart failure with preserved ejection fraction.mp4
